NCT02249130View on ClinicalTrials.gov

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

April 30, 2000

Conditions
HIV Infections
Interventions
DRUG

Tipranavir (TPV)

DRUG

Ritonavir (RTV)

DRUG

Delavirdine (DLV)

DRUG

Zidovudine (ZDV)

DRUG

Lamivudine (3TC)

DRUG

Stavudine (d4T)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02249130 - Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir | Biotech Hunter | Biotech Hunter